Saturday, November 2, 2013 La QuintaMedical Center 4431 Horizon Hill Blvd San Antonio, TX 78229 Sponsored by Alamo City Cancer Council & Cancer Care Centers of South Texas A review of benign & malignant hematological disorders, for physicians, nurses & pharmacists Agenda 7:308:00 am Breakfast & checkin 8:008:15 am WelcomeDr. Sharon Wilks 8:158:45 am Brief Overview of Hematopoesis, Dr. Sharon Wilks 8:459:30 am Preop Management of Coagulation Disorders Michael Osswald, MD 9:309:40 am Break 9:4010:25 am Disorders Related to ThrombocytopeniaAlexander Zweibach, MD 10:2511:10 am Anemia of Chronic disease and other Hypoproliferative AnemiasManuel Santiago. MD 11:1011:55 am Leukopenia & Leukocytosis Disorders Sridhar Beeram, MD 11:5512:40 pm Lunch 12:401:25 pm Multiple Myeloma or Malignant Hematology , Allyson Harroff, MD 1:252:10 pm Myelodysplastic SyndromesRoger Lyons, MD 2:102:20 pm Break 2:203:05 pm Overview of Lymphoma David Gordon, MD 3:05 4:05 pm Barriers to Effective Pain Management: Ethics Greg Guzley, MD https://www.surveymonkey.com/s/5FCFFK7 Payment: check or credit card Through 9/27/2013 Early Registration Fee: $185.00 9/28 10/25/2013 Regular Fee: $210.00 10/26/2013 to onsite Late/Onsite Fee: $235.00 Information email [email protected] CNE: The University of Texas Health Science Center San Antonio School of Nursing is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. This program provides up to 6.75 contact hours. CME – has been applied for The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for .675 CEUs (6.75 contact hours) of continuing education credit. In order to receive 6.75 contact hours of CE credit, the participant must attend/participate in all sessions of the program, and complete the online evaluations for each session at the conclusion of the program. Benign & Malignant Hematology What Providers and Clinicians Should Know